4Sc Stock

4Sc ROE

Delisted

The Return on Equity (ROE) of 4Sc (VSC.DE) as of Aug 22, 2026 is -108.07 %. In the previous year, Return on Equity (ROE) was -36.75 % — a change of 194.08% (lower).

ROE

-108.07 %

YoY

194.08%

Last updated:

In 2026, 4Sc's return on equity (ROE) was -108.07 %, a 194.08% increase from the -36.75 % ROE in the previous year.

Access this data via the Eulerpool API
Get Free API Key

4Sc Stock analysis

What does 4Sc do? The 4Sc AG is a German biotechnology company specializing in the discovery and development of drugs for numerous indications. It was founded in 2007 and focuses on innovative immunotherapies against cancer, autoimmune diseases, and inflammation. The company's goal is to bring promising drug candidates to Phase IIb clinical trials and then license them to partner companies. Its business model involves working with academic and clinical institutions to research and expand its pipeline. The company's portfolio is divided into three main areas: oncology, autoimmune diseases, and inflammation. It develops drugs that utilize the body's immune system to target cancer cells, inhibit inflammation for autoimmune diseases, and specifically target inflammation for other conditions. Overall, 4Sc AG aims to discover and develop novel drugs that can help patients with severe medical conditions. 4Sc is one of the most popular companies on Eulerpool.

ROE Details

Decoding 4Sc's Return on Equity (ROE)

4Sc's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing 4Sc's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

4Sc's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in 4Sc’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about 4Sc stock

Return on Equity (ROE) of 4Sc is -108.07 % in 2026.

Return on Equity (ROE) of 4Sc changed from -36.75 % to -108.07 %, representing a 194.08% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) 4Sc since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s 4Sc with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API
Get Free API Key

Profitability — 4Sc

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — 4Sc